Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
DiamiR, LLC, a molecular diagnostics company, have announced the publication entitled "Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study" in Aging. Mild Cognitive Impairment is a condition characteristic of early stages of many neurodegenerative diseases, including Alzheimer's disease. The article can be accessed online here.
DiamiR reported that two families of microRNA biomarkers, miR-132 and miR-134 families, detect Mild Cognitive Impairment with the overall accuracy of 96 percent and 87 percent respectively, when plasma samples of Mild Cognitive Impairment patients are compared to plasma samples of age/gender matched control subjects. The two families of biomarkers were identified among neurite/synapse enriched microRNAs and paired with brain-enriched microRNA normalizers using proprietary algorithms and software developed at DiamiR. The biomarkers are believed to reflect pathological processes underlying synaptic dysfunction and destruction characteristic of an early, preclinical stage of dementia development. This biomarker validation study follows pilot, feasibility and small longitudinal studies reported by DiamiR scientists in 2012.
"The results of this study are highly encouraging for the development of a test for early detection of Mild Cognitive Impairment, a condition affecting millions of Americans. The reported data validates DiamiR's innovative approach of using organ-enriched microRNAs for early detection of a pathology, when therapeutic intervention as well as life style changes are much more likely to have a meaningful positive impact," said Dr. Samuil Umansky, President and CSO of DiamiR. The framework of DiamiR's approach and additional applications in the areas of cancer and inflammatory diseases are reported in the Journal of Translational Medicine and can be accessed online at http://www.translational-medicine.com/content/11/1/304/abstract.
"There is a great need for easily accessible, cost effective, noninvasive diagnostics of early stages of Alzheimer's disease," said Dr. Kira Sheinerman, CEO of DiamiR. "Early disease detection, preferably at an asymptomatic stage, could lead to more efficient enrollment into clinical trials and enable effective treatment as well as better planning by patients and caregivers. As the next steps, we will focus on conducting larger studies and developing a test with the goal of making it available to the scientific and medical community as quickly as possible."
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Alzheimer's / Dementia category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
DiamiR, . "Validation of two families of brain-enriched microRNAs as highly promising blood-based biomarkers of mild cognitive impairment." Medical News Today. MediLexicon, Intl., 6 Jan. 2014. Web.
24 Apr. 2014. <http://www.medicalnewstoday.com/releases/270761>
DiamiR, . (2014, January 6). "Validation of two families of brain-enriched microRNAs as highly promising blood-based biomarkers of mild cognitive impairment." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/270761.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.